Illumina, Inc. (NASDAQ:ILMN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Illumina, Inc. (NASDAQ:ILMN) have received a consensus recommendation of “Moderate Buy” from the twenty-four ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, thirteen have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $164.00.

A number of equities analysts have recently commented on the stock. UBS Group lifted their target price on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. TD Cowen lifted their price objective on shares of Illumina from $166.00 to $177.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Royal Bank of Canada increased their target price on shares of Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 5th. Stephens boosted their price target on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a research report on Tuesday, November 12th. Finally, Argus raised Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research note on Wednesday, August 28th.

Hedge Funds Weigh In On Illumina

Several hedge funds have recently bought and sold shares of ILMN. Bank of New York Mellon Corp grew its holdings in Illumina by 7.2% in the second quarter. Bank of New York Mellon Corp now owns 3,039,538 shares of the life sciences company’s stock valued at $317,267,000 after purchasing an additional 204,043 shares during the last quarter. Geode Capital Management LLC grew its stake in Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after acquiring an additional 48,018 shares during the last quarter. Primecap Management Co. CA increased its holdings in Illumina by 3.6% during the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock valued at $328,158,000 after acquiring an additional 87,599 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock valued at $282,735,000 after acquiring an additional 625,245 shares in the last quarter. Finally, Millennium Management LLC raised its position in Illumina by 305.0% during the second quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock worth $155,067,000 after acquiring an additional 1,118,747 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Stock Performance

Shares of ILMN stock opened at $139.91 on Friday. The stock’s 50-day moving average is $142.90 and its two-hundred day moving average is $126.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. Illumina has a 1 year low of $100.08 and a 1 year high of $156.66. The firm has a market cap of $22.19 billion, a price-to-earnings ratio of -14.05 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. Illumina had a positive return on equity of 7.29% and a negative net margin of 36.10%. The business’s revenue was down 3.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.33 EPS. Analysts predict that Illumina will post 4.11 earnings per share for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.